Retina Implant AG, a leading developer of subretinal implants for the visually impaired, is proud to announce Co-Founder and Chairman Eberhart Zrenner, M.D. was invited to present the exciting results of clinical trials he has been leading since 2005 by the American Academy of Ophthalmology at this year's annual meeting that took place October 16-19 at McCormick Place in Chicago, Ill.
“As we continue on with our second clinical trial, we look forward to expanding on the lessons learned during our first trial by following patients as they return home.”
Due to personal reasons, Dr. Zrenner was unable to attend. Dr. Walter-G. Wrobel, CEO of Retina Implant AG, delivered the presentation titled, "Subretinal Implants for Retinitis Pigmentosa" as part of AAO's Retina Subspecialty Day on Saturday, October 16. The presentation discussed findings from Retina Implant's first clinical trial which began in November 2005 and involved implanting 11 patients with a 1500 electrode microchip subretinally. Dr. Wrobel explained how the trial was carried out, the subretinal technique to implantation, and the visual results achieved by patients including the ability to recognize foreign objects and read at a basic level.
"The stellar results achieved during our first clinical trial validate our subretinal approach to implantation which we believe is the key to restoring useful vision for patients blind by retinitis pigmentosa," said Walter-G. Wrobel, CEO of Retina Implant AG. "As we continue on with our second clinical trial, we look forward to expanding on the lessons learned during our first trial by following patients as they return home."
Retina Implant began their second clinical trial earlier this year in Germany with plans to expand the trial to other European countries including the U.K. and Italy. In this clinical trial patients will receive the 1500 electrode implant permanently. Pending positive results from their second clinical trial, Retina Implant intends to submit for CE mark approval.
Cycles of a diet that mimics fasting can reduce signs of immune system aging, as well as insulin resistance and liver fat